Cash from Operations (TTM) Chart

View Cash from Operations (TTM) for RLYB.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (TTM) Chart
Start Trial

Historical Cash from Operations (TTM) Data

View and export this data back to 2020. Start Trial.
Date Value
June 30, 2026 26.71M
March 31, 2026 -27.59M
December 31, 2025 -29.81M
September 30, 2025 -35.00M
June 30, 2025 -41.99M
March 31, 2025 -44.03M
December 31, 2024 -49.28M
September 30, 2024 -51.06M
June 30, 2024 -53.99M
March 31, 2024 -56.96M
December 31, 2023 -60.26M
September 30, 2023 -63.88M
Date Value
June 30, 2023 -62.15M
March 31, 2023 -62.32M
December 31, 2022 -57.28M
September 30, 2022 -51.91M
June 30, 2022 -48.04M
March 31, 2022 -47.34M
December 31, 2021 -45.53M
September 30, 2021 -42.91M
June 30, 2021 -37.66M
March 31, 2021 -28.43M
December 31, 2020 -22.04M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (TTM) Range, Past 5 Years

View Cash from Operations (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (TTM) Benchmarks

View Cash from Operations (TTM) Benchmarks
Start Trial
Q32 Bio, Inc. -19.83M
Beam Therapeutics, Inc. -359.38M
C4 Therapeutics, Inc. -84.87M
Cullinan Therapeutics, Inc. -159.25M
Arrowhead Pharmaceuticals, Inc. -59.06M